Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head...
BEIJING and BRIDGEWATER, N.J., Dec. 18, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087.SH), is pleased to announce that the Food and Drug Administration (" FDA ") has cleared the Investigational New Drug (IND) application for GZR18 Injection to conduct a phase 2 clinical trial, a head-to-head...
Tokyo Lifestyle Co., Ltd. Reports First Six Months of Fiscal Year 2025 Financial Results
TOKYO, Dec. 18, 2024 /PRNewswire/ -- Tokyo Lifestyle Co., Ltd. ("Tokyo Lifestyle" or the "Company") (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, as well as other products in Hong Kong, Japan, North America and the United Kingdom, today announced its unaudited financial results for the first six months of fiscal year...
Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation
BEIJING, Dec. 18, 2024 /PRNewswire/ -- Seoul 120 hotline has contributed to efficient city operation, according to the Evaluation Report on Worldwide City Hotline Services and Governance Effectiveness (2024) released on Wednesday. Photo shows the consultation interface of the Seoul 120 hotline in Chinese. The report, jointly released by the Xinhua Research Center for Digital Government and Institute...
Samsung invests in Generate: Biomedicines to advance AI-driven protein therapeutics discovery
- Samsung Life Science Fund invests in Generate:Biomedicines, a Flagship Pioneering company leading in AI-enabled protein therapeutics discovery and development - Investment highlights Samsung's dedication to advancing innovation and creating a robust ecosystem for AI-enabled therapeutic development INCHEON, South Korea, Dec. 18, 2024 /PRNewswire/ -- Samsung announced today it has invested in Generate:...
U.S. FDA approves Celltrion’s STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab)
STEQEYMA (CT-P43) is approved for both adult and pediatric patients with plaque psoriasis (PsO) and active psoriatic arthritis (PsA) as well as adults with Crohn's disease (CD) and ulcerative colitis (UC) STEQEYMA is a strategic addition to Celltrion's portfolio, expanding the portfolio and building on Celltrion's expertise in immunology STEQEYMA...
TPIsoftware Expedites Underwriting and Claims Processing for Cathay Life Insurance
TAIPEI, Dec. 18, 2024 /PRNewswire/ -- As a leading expert in Fintech and Insurtech, TPIsoftware has once showcased its digital expertise in delivering tech-driven solutions for Cathay Life Insurance. With Cathay utilizing TPIsoftware's Business Process Management (BPM) platform digiFlexis and digiMars, a big data management platform designed to elevate MongoDB community edition for...
Neurizon Files IND Application to Support HEALEY ALS Platform Trial
Highlights: IND application submission to the U.S. Food and Drug Administration (FDA) is a pivotal step in initiating a Phase 2/3 clinical study for NUZ-001 The IND is a comprehensive dossier of information, including animal and human studies, pharmacokinetic analyses, toxicology studies, and manufacturing information for NUZ-001 The FDA has a...
Nutiani Unveils Top Five Consumer Trends for 2025
TOKYO, Dec. 18, 2024 /PRNewswire/ -- Nutrition science solutions brand Nutiani recently announced its top five consumer trends for 2025 in its live Health & Nutrition Trends Webcast. Presented by Rebecca Cuthbertson, Head of Marketing, Advanced Nutrition, Fonterra, and Pooja Passi, Head of Insights, Fonterra, the five trends shared were derived from Nutiani's consumer studies, social listening trends, and...
Everest Medicines Announces the First Prescription of VELSIPITY® in the Greater Bay Area, Officially Benefiting Mainland China Patients
SHANGHAI, Dec. 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription for VELSIPITY® has been written at Foshan Fosun Chancheng Hospital in Guangdong, under the "Hong Kong and Macau Medicine and Equipment Connect" policy, which...
Ubie Growth in 2024 Driven by Industry Leading Recognition, Collaborations with Patient Advocacy Groups and an Expanded Reach of More Than 4 Million Users
Strategic investment from Google and acceptance into Mayo Clinic Platform Accelerate program show an increasing understanding of Ubie's value to patients and healthcare Key platform innovations have led to increased user engagement, with a 30% increase in call to action engagement Results from two new analyses support Ubie's AI Symptom Checker's...
